vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and VIRCO MFG CORPORATION (VIRC). Click either name above to swap in a different company.

VIRCO MFG CORPORATION is the larger business by last-quarter revenue ($47.6M vs $38.3M, roughly 1.2× ImmunityBio, Inc.). VIRCO MFG CORPORATION runs the higher net margin — -2.8% vs -161.8%, a 159.0% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -42.3%). VIRCO MFG CORPORATION produced more free cash flow last quarter ($24.5M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

The Virco Manufacturing Corporation, more commonly known as Virco, is an American furniture manufacturer based in Torrance, California which focuses on providing products for educational markets. The principal products of the company include student desks and activity tables, school and office seating, computer stations, lightweight folding tables, and upholstered chairs.

IBRX vs VIRC — Head-to-Head

Bigger by revenue
VIRC
VIRC
1.2× larger
VIRC
$47.6M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+449.3% gap
IBRX
407.0%
-42.3%
VIRC
Higher net margin
VIRC
VIRC
159.0% more per $
VIRC
-2.8%
-161.8%
IBRX
More free cash flow
VIRC
VIRC
$95.8M more FCF
VIRC
$24.5M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
IBRX
IBRX
VIRC
VIRC
Revenue
$38.3M
$47.6M
Net Profit
$-61.9M
$-1.3M
Gross Margin
99.0%
38.0%
Operating Margin
-169.0%
-3.6%
Net Margin
-161.8%
-2.8%
Revenue YoY
407.0%
-42.3%
Net Profit YoY
-4.7%
-115.8%
EPS (diluted)
$-0.06
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
VIRC
VIRC
Q4 25
$38.3M
$47.6M
Q3 25
$32.1M
$92.1M
Q2 25
$26.4M
$33.8M
Q1 25
$16.5M
$28.5M
Q4 24
$7.6M
$82.6M
Q3 24
$6.1M
$108.4M
Q2 24
$46.7M
Q1 24
$42.6M
Net Profit
IBRX
IBRX
VIRC
VIRC
Q4 25
$-61.9M
$-1.3M
Q3 25
$-67.3M
$10.2M
Q2 25
$-92.6M
$732.0K
Q1 25
$-129.6M
$-5.7M
Q4 24
$-59.2M
$8.4M
Q3 24
$-85.7M
$16.8M
Q2 24
$2.1M
Q1 24
$-2.3M
Gross Margin
IBRX
IBRX
VIRC
VIRC
Q4 25
99.0%
38.0%
Q3 25
99.4%
44.4%
Q2 25
99.5%
47.5%
Q1 25
99.6%
26.2%
Q4 24
44.4%
Q3 24
46.3%
Q2 24
43.5%
Q1 24
37.7%
Operating Margin
IBRX
IBRX
VIRC
VIRC
Q4 25
-169.0%
-3.6%
Q3 25
-173.5%
16.7%
Q2 25
-269.8%
-0.3%
Q1 25
-390.1%
-28.5%
Q4 24
-919.0%
13.5%
Q3 24
-1314.3%
20.2%
Q2 24
6.4%
Q1 24
-6.5%
Net Margin
IBRX
IBRX
VIRC
VIRC
Q4 25
-161.8%
-2.8%
Q3 25
-209.8%
11.1%
Q2 25
-350.3%
2.2%
Q1 25
-784.9%
-20.1%
Q4 24
-783.4%
10.2%
Q3 24
-1404.0%
15.5%
Q2 24
4.6%
Q1 24
-5.5%
EPS (diluted)
IBRX
IBRX
VIRC
VIRC
Q4 25
$-0.06
$-0.08
Q3 25
$-0.07
$0.65
Q2 25
$-0.10
$0.05
Q1 25
$-0.15
$-0.37
Q4 24
$-0.08
$0.52
Q3 24
$-0.14
$1.04
Q2 24
$0.13
Q1 24
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
VIRC
VIRC
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
$3.9M
Stockholders' EquityBook value
$-500.5M
$113.6M
Total Assets
$501.9M
$181.5M
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
VIRC
VIRC
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Q1 24
$5.3M
Total Debt
IBRX
IBRX
VIRC
VIRC
Q4 25
$3.9M
Q3 25
$4.0M
Q2 25
$4.1M
Q1 25
$4.1M
Q4 24
$4.2M
Q3 24
$4.3M
Q2 24
$7.0M
Q1 24
$4.4M
Stockholders' Equity
IBRX
IBRX
VIRC
VIRC
Q4 25
$-500.5M
$113.6M
Q3 25
$-524.3M
$115.4M
Q2 25
$-570.7M
$105.6M
Q1 25
$-591.4M
$109.3M
Q4 24
$-489.1M
$115.9M
Q3 24
$-745.1M
$107.8M
Q2 24
$91.6M
Q1 24
$91.2M
Total Assets
IBRX
IBRX
VIRC
VIRC
Q4 25
$501.9M
$181.5M
Q3 25
$519.0M
$198.6M
Q2 25
$402.1M
$183.8M
Q1 25
$303.8M
$191.9M
Q4 24
$382.9M
$210.1M
Q3 24
$364.6M
$216.3M
Q2 24
$152.5M
Q1 24
$146.4M
Debt / Equity
IBRX
IBRX
VIRC
VIRC
Q4 25
0.03×
Q3 25
0.03×
Q2 25
0.04×
Q1 25
0.04×
Q4 24
0.04×
Q3 24
0.04×
Q2 24
0.08×
Q1 24
0.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
VIRC
VIRC
Operating Cash FlowLast quarter
$-70.4M
$25.8M
Free Cash FlowOCF − Capex
$-71.3M
$24.5M
FCF MarginFCF / Revenue
-186.2%
51.5%
Capex IntensityCapex / Revenue
2.4%
2.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$-4.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
VIRC
VIRC
Q4 25
$-70.4M
$25.8M
Q3 25
$-68.9M
$3.2M
Q2 25
$-79.7M
$-19.0M
Q1 25
$-85.9M
$-8.3M
Q4 24
$-85.1M
$33.5M
Q3 24
$-98.8M
$12.5M
Q2 24
$-4.5M
Q1 24
$4.7M
Free Cash Flow
IBRX
IBRX
VIRC
VIRC
Q4 25
$-71.3M
$24.5M
Q3 25
$-69.6M
$1.8M
Q2 25
$-80.8M
$-21.5M
Q1 25
$-87.0M
$-9.2M
Q4 24
$-87.3M
$31.0M
Q3 24
$-101.6M
$10.7M
Q2 24
$-5.6M
Q1 24
$4.0M
FCF Margin
IBRX
IBRX
VIRC
VIRC
Q4 25
-186.2%
51.5%
Q3 25
-217.2%
2.0%
Q2 25
-305.9%
-63.6%
Q1 25
-526.9%
-32.4%
Q4 24
-1155.4%
37.5%
Q3 24
-1663.2%
9.8%
Q2 24
-12.0%
Q1 24
9.5%
Capex Intensity
IBRX
IBRX
VIRC
VIRC
Q4 25
2.4%
2.7%
Q3 25
2.3%
1.5%
Q2 25
4.1%
7.2%
Q1 25
6.8%
3.3%
Q4 24
28.0%
3.0%
Q3 24
45.7%
1.7%
Q2 24
2.3%
Q1 24
1.5%
Cash Conversion
IBRX
IBRX
VIRC
VIRC
Q4 25
Q3 25
0.31×
Q2 25
-26.00×
Q1 25
Q4 24
3.98×
Q3 24
0.74×
Q2 24
-2.11×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons